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Abstract
Introduction: Liver transplantation (LT) in cirrhotics is characterized by severe
coagulopathy, associated with a well documented heparin-like effect (HLE) seen by
thromboelastography (TEG
TM) after reperfusion. The amount of HLE present in
patients with acute liver failure (ALF) and its role in their bleeding tendency before LT
has not been investigated. Aim: To investigate the presence and extent of HLE in
patients with ALFundergoing LTand to comparethe extent of HLE in this groupwith a
group of cirrhotics undergoing LT. Material and Methods: Ten consecutive ALF and 10
cirrhotic patients undergoing LTwere included. TEG
TM (with and without heparinase
I), surrogate total thrombin generation (TTG) derived by TEG
TM and haemodynamic
variables were recorded for every stage of the LT. HLE was deﬁned as a correction of
r1k times on TEG
TMof more than 50% by the addition of heparinase I. Results: Before
incision, patients with ALF showed a signiﬁcantly greater HLE compared with patients
with cirrhosis (r1k time: 66min corrected to 29 vs 45min corrected to 32min,
P=0.001). After reperfusion, all the patients showed extensive HLE, without any
difference between the two groups. Despite the greater HLE, patients with ALF showed
similar TTG compared with the cirrhotic group. By the end of the operation, the extent
of the HLE was greatly reduced in both the groups. Conclusions: Before transplanta-
tion, patients with ALF have a greater HLE than patients with liver cirrhosis. However,
this did not affect the thrombin generation calculated by TEG
TM and resolved after
transplantation.
Acute liver failure (ALF) is characterized by severe and sudden
hepatic dysfunction in a previously healthy individual, resulting
in a high mortality despite the use of liver transplantation (LT).
Complications are hepatic encephalopathy, jaundice and severe
coagulopathy. Multiorgan failure is common (1). The coagulo-
pathy comprises a wide spectrum of haemostatic changes,
including thrombocytopaenia, reduced platelet function and
reduced concentrations of many coagulation factors (2). Con-
centrations of coagulation factors and other changes in coagu-
lation are used prognostically as indications for LT: King’s
college criteria includes prothrombin time (PT) (3) and the
Clichy criteria uses factor V concentrations (4). Although a
prolongation of PT is due to the poor synthetic function of the
liver and results in ‘anticoagulation’, patients with ALF can
show microvascular thrombi within the hepatic vessels due to a
disequilibrium between pro- and anticoagulant factors (5).
Recently, a decreased protein C activation and hypercoagul-
ability have been demonstrated in six patients with ALF (6).
Although spontaneous bleeding is not directly related to
commonly measured coagulation factors, the use of frozen
plasma is mandatory before invasive procedures (i.e. intracra-
nial pressure monitoring) as otherwise bleeding can occur (7).
Inﬂammation and endothelial damage could be additional
factors impairing coagulation in these patients. Inﬂammation
accompanied by a sepsis-like syndrome is common in
ALF patients, particularly following paracetamol overdose (8).
Natural anticoagulants [glycosaminoglycans (GAGs)] normally
linked to the endothelium could be released by endothelial
damage and could contribute to the coagulopathy as shown in
patients with chronic liver disease (9), but this has never been
evaluated in patients with ALF.
Thromboelastography (TEG
TM) is a rapid method to assess
the entire coagulation process using whole blood. The addition
of heparinase I, which cleaves heparin-like compounds, can
reveal the presence of a heparin-like effect (HLE) due to an
increased amount of endogenous anticoagulants (GAGs) (10).
A HLE has been demonstrated in patients with liver disease and
bacterial infections, correlating with an anti-Xa activity in some
(9, 11).
A new development of TEG
TM technology has allowed the
production of a VCURVE
TM from the TEG
TM trace (12). Previous
work using thrombin–antithrombin measurements had postu-
lated that thrombin generation is normal in cirrhosis and
constant during orthotopic liver transplantation (OLT),
although it may increase after reperfusion of the graft (13).
The data produced by the VCURVE
TM is based on a mathematical
model derived from the TEG
TM data. The measurements
produced from the VCURVE
TM (Haemoscope Corp, Skokie, IL,
USA) software give an indication of the speed of the thrombin
burst [time to maximal generation (TMG)] and its intensity
[maximal thrombin generation (MTG), the peak of the throm-
bin generation curve] as well as the total thrombin generated
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marker of thrombin generation. These describe how the char-
acteristics of thrombin generation differ when a patient is
hypocoagulable, resulting in a longer TMG and a smaller MTG
(12). This methodology has been evaluated against the standard
thrombin–antithrombin enzyme-linked immunosorbent assay
method of measuring thrombin generation and was found to
have a high correlation (r=0.94) (14). Thus, the thrombin
generation curve (VCURVE) has potential in investigating the
coagulation abnormalities observed in ALF.
The aim of our study was to evaluate the contribution
of endogenous heparinoids evaluated by heparinase I-modiﬁed
TEG
TM in the coagulopathy of patients with ALF undergoing
LT. This liver failure group was compared with a group of
patients with cirrhosis undergoing LT and a control group of
healthy volunteers.
Methods
Thirty subjects were enrolled in this study; 10 patients with ALF
and 10 patients with liver cirrhosis, all 20 undergoing LT. Ten
healthy volunteers with no known haemostatic disorders and
not taking medication having an inﬂuence on coagulation
within the preceding 30 days were used as the control group.
History of recent bleeding, documented bacterial infections,
presence of hepatocellular carcinoma and cholestatic aetiology
of liver disease were exclusion criteria for the cirrhotic group,
the latter two being known as procoagulant conditions. Patients
with ALF and with cirrhosis who received blood products in the
previous week were excluded from the study. All lines and ﬂush
bags during transplant were nonheparinized. None of the
patients received protamine.
All the patients had given informed consent for collection of
10ml of whole noncitrated blood into a noncitrated tube
(Sarstedt Monovette
s tubes, Sarstedt, Leicester, UK) with a
21G needle with a light tourniquet, avoiding stasis and platelet
activation. In ALF and cirrhotic patients, 10ml of blood was
collected from a dedicated nonheparinized arterial cannula at
the stages detailed below. Samples were collected into a plain
syringe and were not activated by celite/kaolin.
Three hundred and sixty microlitres of whole blood was used
for TEG
TM analysis and the remaining blood was centrifuged at
3000g for 12min at 41C. The plasma was then removed and
centrifuged at 3000g for a further 12min at 41C to obtain
platelet-poor plasma. Samples were aliquoted into Sarstedt
cryotubes (Sarstedt, Leicester, UK) and stored at  701.
Thromboelastography
Soon after the drawing of blood, 360ml of whole blood was
reverse pipetted into a plain and a heparinase-coated TEG
TM
cup. Samples were run simultaneously and immediately on
blood collection as per manufacturer’s recommendation.
TEG
TM was performed using a computerized thromboelasto-
graph (Haemoscope Corp, Skokie, IL, USA).
The blood was mixed with the cuvette by lowering the pin
three times and covered with mineral oil to prevent evaporation
during analysis. The TEG
TM was allowed to run till the
maximum amplitude (MA) was reached.
Paired TEG
TM traces (with and without heparinase) were
examined at ﬁve stages before and during LT: 1, at baseline; 2,
1h into the dissection; 3, half an hour into the anhepatic
period; 4, half an hour after reperfusion; 5, at the end of the
operation.
We evaluated the differences between the native TEG
TM
parameters and the same parameters obtained after the addi-
tion of heparinase I. The TEG
TM parameters (r=reaction time,
k=clotting time, a=alpha angle, MA=maximum amplitude)
were generated and recorded automatically by a computer: r is
the time from sample until the TEG
TM trace amplitude reaches
2mm, which represents the rate of initial ﬁbrin formation and
is functionally related to plasma clotting factors and circulating
inhibitor activity; k is measured from r to the point where the
amplitude of the tracing reaches 20mm – it is the time taken to
reach a standard clot ﬁrmness and is affected by the activity of
the intrinsic clotting factors, ﬁbrinogen and platelets; a is the
angle formed by the slope of the TEG
TM tracing from the r to
the k value, representing the rate of clot growth and describing
the polymerization of the structural elements involved in
clotting; MA is the maximum variation on TEG
TM parameters
within the same group.
Deﬁnitions of HLE vary in the literature and, based on the
percentage of correction of the TEG
TM trace by addition of
heparinase, we calculated the percentage correction of the r1k
times on TEG
TM with the addition of heparinase as shown:
ðr þ kÞ time native sample  ð r þ kÞtime heparinase sample
ðr þ kÞtime native sample
  100
Heparin-like effect was deﬁned as a correction of r1k times
on TEG
TM of more than 50% by the addition of heparinase.
Those with greater than an 80% correction were categorized as
demonstrating severe HLE.
The TEG
TM traces and appropriate software (VCURVE
TM)
were used to derive the TTG at each stage according to the
paper by Sorensen et al. (15). The TTG data were examined for
differences in the native traces of those with and without HLE.
Standard coagulation tests
The PT (rabbit HS-Plus-Fib; Instrumentation Laboratory,
Warrington, UK), activated tissue thromboplastin time (APTT)
(lyophilized APTT reagent; Instrumentation Laboratory) and
thrombin time (bovine thrombin; Diagnostic Reagents, Thame,
UK) were performed on stored plasma aliquots for each
concentration of GAG using standard techniques with an ACL
FUTURA coagulometer (Instrumentation Laboratory).
Statistical analysis
The two-tailednonparametric Wilcoxon matched-pairs testwas
used to compare the basal and heparinase I TEG
TM at every
stage during OLT. Differences of standard coagulation and
TEG
TM parameters between the three groups of patients were
evaluated by the Kruskal–Wallis method and between the two
groups by the Mann–Whitney U test; Po0.05 was considered
statistically signiﬁcant. For all calculations, SPSS for Windows
version 10 (SPSS Inc., Chicago, Illinois, USA) was used.
Results
Patients
Ten patients with ALF, 10 patients with liver cirrhosis under-
going LT and 10 healthy volunteers as control group were
enrolled. Characteristics of patients and controls are shown in
Table 1.
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Before skin incision, patients with ALF showed worse standard
coagulation parameters compared with cirrhotic patients and
with the control group.
Thromboelastography showed that patients with ALF had
signiﬁcant prolongation of r and k times, lower a angle
and reduced MA at TEG
TM compared with both the cirrhotic
and the control groups. Details on standard coagulation tests
and TEG
TM parameters and signiﬁcant differences are shown in
Table 2.
Despite the different thromboelastographical parameters,
analysis of the VCURVE as surrogate of TTG revealed similar
values among the three groups (Table 2).
Reversal of clotting inhibition by heparinase I
Heparinase I-modiﬁed TEG
TM demonstrated a HLE, by deﬁni-
tion a correction of r1k times on TEG
TM of more than 50% in
one out of 10 patients with cirrhosis and nine out of 10 patients
with ALF (P=0.0016; Fisher’s exact test). Four of the nine
patients with ALF and HLE had severe HLE (reduction of r1k
times by addition of heparinase I480%; Fig. 1a and b).
The differences (correction of r1k times) in heparinase I-
modiﬁed TEG
TM between cirrhotic and ALF groups were
statistically signiﬁcant before incision (stage 1) (P=0.01) and
also during dissection (phase 2) (P=0.03). Patients with
cirrhosis had no signiﬁcant correction of TEG
TM parameters
after addition of heparinase I in all the stages before reperfu-
sion, showing no HLE before transplantation. As expected, after
reperfusion, HLE was severe in both cirrhotic and ALF patients
(correction of TEG
TM trace by more than 80% after addition of
heparinase I).
A graphical representation of r1k times at baseline and
during different stages during LT in native and heparinase
I-modiﬁed TEG
TM in ALF and cirrhotic patients is shown in
Figure 2a and b.
As previously reported (20), there was no difference between
TEG
TM and heparinase I-modiﬁed TEG
TM parameters in
healthy controls (r 18.7 2.4 seconds vs 20.6 5.4 seconds; k
7.5s 3.6 seconds vs 6.8 2.3 seconds; a angle 27.4 4.81 vs
29.8 5.51: MA 47.6 7.9 vs 49.6 8.6mm).
When the magnitude of the effect of heparinase I was
compared between ALF and cirrhotic patients, ALF patients
had a greater difference between the r1k times native and after
the heparinase I addition, before incision and during the
dissection phases (Fig. 3).
Discussion
We report for the ﬁrst time the contribution of endogenous
heparinoids to the abnormalities in coagulation of patients with
ALF who require LT. ALF is characterized bya reduced synthesis
of all coagulation factors, both pro- and anticoagulant, but the
von Willebrand factor and factor VIII are released by the
endothelium (16). In particular, factor VIII is increased because
it is released by endothelial cells during the underlying inﬂam-
mation process.
Inﬂammation and increased levels of interleukin-6 and
tumour necrosis factor-a seem to have an important role
leading to increased synthesis of tissue factor and promoting
thrombin formation (17).
Increased release of cytokines can lead to endothelial injury
together with the sepsis-like syndrome [systemic inﬂammatory
response syndrome (SIRS)], which is well documented in ALF.
This could lead to the release of endogenous heparinoids, which
are synthesized by endothelial cells and are naturally bound to
the endothelium of the vessels, preventing spontaneous throm-
bosis (18). Moreover, during sepsis or SIRS, mast cells can
release heparin-like substances (19). For the ﬁrst time, we
reported a HLE in 90% of the patients with ALF, demonstrating
that endogenous GAGs are responsible for a major part of
anticoagulation. In about 50% of these, addition of heparinase
I was able to correct the trace by more than 80%, as shown in
Figure 2. Which heparinoid (GAGs) is wholly or in a major part
responsible for this effect cannot be derived from our data. We
have already shown that heparinase I is able to detect not only
the effect of heparan sulphate, which is the major natural
anticoagulant lining the endothelium, but also of dermatan
sulphate (20).
Glycosaminoglycans (heparinoids) are constituents of the
vessel wall and can be bound by the endothelium. Endothelial
cells synthesize heparan sulphate and are also able to bind other
heparin-like substances, such as dermatan and chondroitin
sulphate (21). All these GAGs have anticoagulant properties
and help to maintain coagulationhaemostasis atthe endothelial
Table 1. Characteristics of patients and of the control group
Groups
Acute liver
failure Cirrhosis Controls
Number of subjects 10 10 10
Age (years SD) 42.3 4 53.6 6 38.5 6.5
Sex (M/F) 4/6 7/3 8/2
Aetiology
Alcohol/viral/
cryptogenic/paracetamol
0/2/3/5 6/3/1/0 –
Acute/subacute form 7/3––
Child–Pugh
A/B/C
– 0/7/3 –
MELD
h15/i15
– 4/6 –
F, female; M, male; MELD, model for end-stage liver disease; SD,
standard deviation.
Table 2. Standard coagulation parameters and thromboelastogra-
phical parameters and total thrombin generated derived using
thromboelastography
Acute liver
failure Cirrhosis Controls P
PT (s) 32.6 18.1 19.7 4.5 14.4 0.2 0.029
INR 2.8 1.4 1.6 0.4 1 0.2 0.009
PTT (s) 53.6 15.2 42.7 9.5 34.6 1.4 0.040
PLT (10
9/L) 114.8 86.2 90 11.3 234 30 0.347
r (s) 49.9 31.08 21 5.5 18.7 3.4 0.021
k (s) 22.8 9.3 14.4 9.3 27.4 5.5 0.034
Angle (1) 7.5 7.2 22.8 9.3 27.5 5.5 0.001
MA (mm) 38.9 6.4 44 9.1 47 7.2 0.461
TTG (mm 100) 5333 976 5274 1034 5574 754 0.543
INR, international normalized ratio; k, clotting time; MA, maximum
amplitude; PLT, platelets; PT, prothrombin time; PTT, partial thromboplas-
tin; r, reaction time; TTG: total thrombin generated
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dermatan sulphate has recently been recognized to have im-
portant anticoagulation properties. Dermatan sulphate inhibits
thrombin generation by forming an inactive ternary complex
with heparan cofactor II (20). It has also been shown to be as
effective as heparin in preventing post-operative thrombosis
and it can be used when heparin-induced thrombocytopenia
occurs.
During sepsis, sepsis-like syndrome or infection, the liver is
exposed to a neutrophil-mediated injury, involving both hepa-
tocytes and endothelial cells, which could release heparin-like
substances (heparan sulphate) into the systemic circulation
(22), analogous to what happens during suramin treatment in
patients with metastatic liver disease (23). It is well known that
the liver contains abundant parenchymal deposits of GAGs,
heparan sulphate being predominant (24).
Additionally, and particularly in patients with ALF, the
ability to eliminate circulating GAGs is likely to be greatly
reduced due to the important reduction of liver function.
McKee et al. (25) have shown a reduced hepatic clearance of
heparin in patients with liver cirrhosis and increased serum
levels of heparin sulphate after variceal bleeding. Although
sepsis like syndrome could be an additional factor responsible
for the release of GAGs from the endothelium, the patients in
the ALF group did not show signiﬁcantly different haemody-
namic parameters from cirrhotic patients, although there was a
trend towards a more ‘septic’ picture, with a lower systemic
vascular resistance and a higher cardiac index (data not shown).
In our study, patients with ALF had worse standard coagula-
tion parameters as expected, compared with both the cirrhotic
and the control group, reﬂecting poor synthetic hepatic synth-
esis of coagulation factors (more than haemostatic balance),
which was reﬂected in the abnormal thromboelastographical
parameters. However, despite a slower abnormal velocity of
formation of the clot, VCURVE (calculated by TEG
TM) was not
different either from the controls or from the cirrhotics. This
may be due to the fact that platelets are essential in thrombin
formation and MA (which correlates with platelet function)
was not found to be significantly different between the groups
(26). Sorensen et al. (15) used various amount of tissue factor
(in contrast to our study in which none was used) to activate
the clotting process in the TEG
TM cups, resulting in different
Fig. 1. Native thromboelastography (TEG
TM) (a) and heparinase I TEG
TM (b) in samples collected from a patient with acute liver failure at
baseline before liver transplantation. Signiﬁcantheparin-like effect is shown by the very slow rate of coagulation.Treatment of the sample with
heparinase I signiﬁcantly increased the rate of coagulation, indicating the presence of heparin-like substances.
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thrombin, but it did not result in a significantly different
generation of total thrombin. Avalidation of TEG
TM as a whole
blood test to calculate thrombin generation is needed and the
significance of normal thrombin generation in liver disease is
still to be evaluated clinically, given the bleeding tendency with
invasive procedures.
As expected and already reported, during LT, the coagulation
proﬁles of both ALF and cirrhotic patients show greater
HLE after reperfusion, which subsides by the end of the
operation (27). Estimated thrombin generation after reperfu-
sion was reduced compared with baseline and was similar
between cirrhotics and ALF patients (2430 100mm vs
2198 100mm respectively).
It is well known that during invasive procedures, patients
with ALF have an increased risk of bleeding and correction of
coagulation is indicated (7). Commonly, fresh frozen plasma is
used to correct coagulation in patients with ALF undergoing
invasive procedures and, recently, recombinant thrombin factor
VII has been tried to accelerate the coagulation process (28).
The potential therapeutic implications of our ﬁnding of a
signiﬁcant HLE is not clear at present. The use of protamine in
cases where HLE is present is controversial. Pivalizza et al. (29)
and Bayly and Thick (30) have used protamine in vivo,
demonstrating the reversal of HLE in patients with liver
cirrhosis undergoing LT. The neutralization of the heparin
effect could decrease the peri-operative blood loss, but this is
controversial. Although the neutralization of the HLE could
decrease the peri-operative blood loss, hypercoagulation can be
induced, increasing the risk of vessel thrombosis and the
consequent graft loss (31). The use of speciﬁc drugs (i.e.
Neutralase), which selectively cleave heparinoids, has not been
reported in LT.
We conclude that the presence of HLE contributes signiﬁ-
cantly to the coagulopathy of patients with ALF, and this is not
seen in patients with stable liver cirrhosis. Both groups exhibit
normalthrombingeneration.TheclinicalsigniﬁcanceoftheHLE
in relation to bleeding tendency is not known and needs to be
formally explored. Further work is needed regarding thrombin
generation, which may not be the correct parameter to under-
stand coagulopathy in patients with liver cirrhosis and ALF.
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